Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-473-7700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.07 million
Profitability
Miscellaneous
Employees17
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable
Geron (NASDAQ:GERN) Frequently Asked Questions
What is Geron's stock symbol?
Geron trades on the NASDAQ under the ticker symbol "GERN."
How were Geron's earnings last quarter?
Geron Co. (NASDAQ:GERN) announced its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.06. The biopharmaceutical company had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.10 million. Geron had a negative net margin of 7,044.88% and a negative return on equity of 29.22%. During the same quarter last year, the firm posted $0.24 EPS. View Geron's Earnings History.
When is Geron's next earnings date?
What price target have analysts set for GERN?
5 brokers have issued twelve-month target prices for Geron's stock. Their forecasts range from $3.00 to $4.50. On average, they expect Geron's share price to reach $3.90 in the next twelve months. This suggests a possible upside of 197.7% from the stock's current price. View Analyst Price Targets for Geron.
What is the consensus analysts' recommendation for Geron?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Geron.
Has Geron been receiving favorable news coverage?
News articles about GERN stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Geron earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the stock's share price in the immediate future. View News Stories for Geron.
Who are some of Geron's key competitors?
Some companies that are related to Geron include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).
What other stocks do shareholders of Geron own?
Who are Geron's key executives?
Geron's management team includes the folowing people:
- Dr. John A. Scarlett, CEO, Pres & Chairman (Age 68)
- Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 50)
- Dr. Andrew J. Grethlein, Exec. VP & COO (Age 55)
- Mr. Stephen N. Rosenfield, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 69)
- Ms. Melissa A. Kelly Behrs, Exec. VP & Chief Bus. Officer (Age 55)
Who are Geron's major shareholders?
Geron's stock is owned by a number of of institutional and retail investors. Top institutional investors include SG Americas Securities LLC (0.19%), Rhumbline Advisers (0.15%), Creative Planning (0.06%), Summit X LLC (0.05%) and Commonwealth Equity Services LLC (0.04%). Company insiders that own Geron stock include Melissa Kelly Behrs, Robert J Spiegel and Stephen Rosenfield. View Institutional Ownership Trends for Geron.
Which institutional investors are selling Geron stock?
Which institutional investors are buying Geron stock?
How do I buy shares of Geron?
Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Geron's stock price today?
One share of GERN stock can currently be purchased for approximately $1.31.
How big of a company is Geron?
Geron has a market capitalization of $261.71 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Geron employs 17 workers across the globe.View Additional Information About Geron.
What is Geron's official website?
How can I contact Geron?
Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]
MarketBeat Community Rating for Geron (NASDAQ GERN)
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.
